WHO-Tedros has prevailed: International state of emergency due to monkeypox

Source: Willi Huber, Report24.news, 15 Aug 2024

During the last attempt in 2022, the controversial WHO Director-General Tedros Ghebreyesus single-handedly declared a global health emergency against the expert opinion of his committees. Although some corrupt governments ordered vaccines at the time, the disease, which affects 99 per cent of active homosexuals in the West, was not taken seriously by anyone. It started again yesterday, 14 August 2024. After an “expert summit” in Geneva, Tedros once again declared a state of emergency (PHEIC, a word that sounds like “fake” when pronounced). Vaccine manufacturers already have dollar signs in their eyes.
Many are now asking themselves: Will the compulsory vaccination programme already introduced in New Zealand be used for this health emergency? In any case, the WHO has had the power to order such and other measures since the changes to the treaties lately. The new international health emergency due to an outbreak of monkeypox in the Congo was declared yesterday in accordance with Article 12 of the IHR 2005.

However, the first step, as with Covid-19, must undoubtedly be to scare the population with panic reports from the press. But that will not be so easy with a harmless virus that is dangerous at best in the newspapers and TV news. Even during the last attempt in 2022, the mainstream media found it extremely difficult to find any confirmed, active cases. At the time, we researched the fact that almost exclusively old images from an outbreak 20 years ago were used and not a single report corresponded to current facts.
However, it cannot be said that the mainstream media is not doing its utmost to service the globalist position on a much-desired monkeypox pandemic. Der Spiegel headlines: “If we don’t act now, the situation will explode” and Die Welt reports: WHO declares highest alert level due to Mpox virus in Africa: “World community should be prepared”. The European Union is as usual diligent in supporting vaccine manufacturers. This is what we learn on the EU website: Monkeypox in Africa: EU coordinates procurement/donation of Bavarian-Nordic vaccine.

The mRNA “vaccine” manufacturer BioNTech has announced a loss of 1.1 billion euros for the first half of 2024, but has also stated that most of its sales will be made in the fourth quarter. A total turnover of 3 billion is expected. To relieve some of the pressure on health insurance companies, German Health Minister Lauterbach has already ordered 15 million Covid-19 vaccine doses for the autumn. It is safe to assume that a substantial MPox (monkeypox) vaccine order will follow.
BioNTech and CEPI have already agreed their collaboration for a modRNA injection for MPox in September 2023. After BNT-162b2, we can now recall BNT-166. Attorney Dr Brigitte Röhrig explains on Telegram:
BioNTech is currently conducting a Phase I/II clinical trial for the modRNA injection BNT-166a against MPox. This phase I/II dose escalation study (https://clinicaltrials.gov/study/NCT05988203) is entitled: “Randomised, partially blinded phase I/II dose-escalation study to evaluate the safety and immunogenicity of RNA-based Mpox vaccine candidates”.

The study is being conducted with the quadrivalent injection candidate BNT166a. Originally, the use of BNT-166c was also planned. However, BioNTech has decided against the use of BNT-166c.
According to clinicaltrials.gov, the trial was scheduled to start on 21 September 2023, shortly after the announcement of the strategic partnership with CEPI. The clinical trial will be conducted at study centres in the USA and the UK. The recruitment status is still stated.
At present, monkeypox is said to be particularly rampant in the Congo, where it usually causes a rash with pustules typical of smallpox. Human-to-human transmission occurs via skin lesions or sexually (which is why the last “outbreak” outside Africa mainly affected homosexuals). Children are said to be particularly at risk.
At any rate, BioNTech is already rejoicing:

“In challenge studies, BNT166a and BNT166c provided complete protection against vaccinia, clade I and clade IIb MPXV. In addition, immunisation with BNT166a was 100% effective in preventing death and suppressing lesions in a fatal clade I MPXV challenge in Javan monkeys.”
As with Covid-19, it is extremely interesting that BioNTech knew months before the current outbreak that a “vaccine” would be needed – and the statement regarding expected billions in profits at the end of 2024 also makes you sit up and take notice.